Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manufacturing.
Related Questions
How will the discontinuation of PCL technology affect PCI Biotech's revenue forecasts and cash flow?
What alternative R&D projects or partnerships is PCI Biotech pursuing to offset the loss of the PCL program?
How might this development halt influence the company's valuation relative to peers in the viral vector manufacturing space?